You are here

Global

WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use

WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use, giving the green light for these vaccines to be rolled out globally through COVAX. The vaccines are produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India.

Problem, Solution, SitRep, or ?: 

Covid may never completely go away but become seasonal like the flu or colds

It's not guaranteed, but it's looking more like the winter months may become cold, flu and COVID-19 season.

Vaccines promise to defang the new coronavirus, taming it so that it's unable to cause serious disease and deaths, or threaten hospitals' ability to deal with patients.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

New COVID-19 cases in U.S. fall for fifth week in a row

(Reuters) - The United States last week reported a 23% drop in new cases of COVID-19 and a 16% fall in the number of people hospitalized with the virus, with both figures declining for a fifth week in a row.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

ANALYSIS" The need for global access to COVID-19 vaccines: production, affordability, allocation, and deployment

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00306-8/fulltext

The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities.

In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. ...

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Covid-Linked Syndrome in Children Is Growing and Cases Are More Severe

Fifteen-year-old Braden Wilson was frightened of Covid-19. He was careful to wear masks and only left his house, in Simi Valley, Calif., for things like orthodontist checkups and visits with his grandparents nearby.

But somehow, the virus found Braden. It wreaked ruthless damage in the form of an inflammatory syndrome that, for unknown reasons, strikes some young people, usually several weeks after infection by the coronavirus.

Doctors at Children’s Hospital Los Angeles put the teenager on a ventilator and a heart-lung bypass machine. But they could not stop his major organs from failing. On Jan. 5, “they officially said he was brain dead,” his mother, Amanda Wilson, recounted, sobbing. “My boy was gone.”

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Covid-19 Vaccines have become a diplomacy tool in third world

NEW DELHI — India, the unmatched vaccine manufacturing power, is giving away millions of doses to neighbors friendly and estranged. It is trying to counter China, which has made doling out shots a central plank of its foreign relations. And the United Arab Emirates, drawing on its oil riches, is buying jabs on behalf of its allies.

The coronavirus vaccine — one of the world’s most in-demand commodities — has become a new currency for international diplomacy.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Global
howdy folks